Acelrx Pharmaceuticals Inc Ret. on equity
What is the Ret. on equity of Acelrx Pharmaceuticals Inc?
The Ret. on equity of Acelrx Pharmaceuticals Inc is -131.91%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on NASDAQ compared to Acelrx Pharmaceuticals Inc
What does Acelrx Pharmaceuticals Inc do?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Companies with ret. on equity similar to Acelrx Pharmaceuticals Inc
- Hertz Global has Ret. on equity of -132.17%
- Hertz Global has Ret. on equity of -132.17%
- Epigenomics AG has Ret. on equity of -132.07%
- Anson Resources has Ret. on equity of -132.05%
- Tasty Concepts has Ret. on equity of -132.02%
- Trine II Acquisition has Ret. on equity of -131.94%
- Acelrx Pharmaceuticals Inc has Ret. on equity of -131.91%
- Immunomedics has Ret. on equity of -131.88%
- Cytosorbents Corp has Ret. on equity of -131.85%
- Zhongtian International has Ret. on equity of -131.80%
- Mirriad Advertising plc has Ret. on equity of -131.78%
- Mercurity Fintech Inc has Ret. on equity of -131.63%
- Guyana Goldfields has Ret. on equity of -131.44%